SCHEDULE 13D: Biogen Proposes Cash Acquisition of Sage Therapeutics at $7.22 Per Share, Building on Existing Collaboration

Biogen Inc. and its subsidiary Biogen MA Inc. have submitted a non-binding proposal to acquire all outstanding shares of Sage Therapeutics, Inc. not currently owned by them for $7.22 per share in cash.

Summary

• Biogen Inc. and its wholly-owned subsidiary, Biogen MA Inc., collectively the "Reporting Persons," have filed a Schedule 13D indicating their beneficial ownership of 6,241,473 shares of Sage Therapeutics, Inc. Common Stock, representing 10.2% of the class outstanding as of October 22, 2024.
• This ownership stems from Biogen MA's purchase of these shares on December 31, 2020, at approximately $104.14 per share, totaling approximately $650.0 million, as part of a Stock Purchase Agreement.
• The Stock Purchase Agreement was executed in connection with a Collaboration and License Agreement dated November 27, 2020, under which Biogen and Sage agreed to jointly develop and commercialize zuranolone (SAGE-217) for psychiatric disorders and SAGE-324 for neurological disorders.
• On January 10, 2025, the Reporting Persons delivered a non-binding proposal to Sage Therapeutics' CEO to acquire all remaining outstanding shares of Common Stock for $7.22 per share in cash.
• The proposal could lead to an acquisition of additional securities, an extraordinary corporate transaction (e.g., merger), delisting from Nasdaq, or other material changes to Sage's business or corporate structure.
• Biogen reserves the right to modify or withdraw the proposal and may acquire or dispose of shares, engage in discussions, or pursue other actions based on its review of Sage's business, market conditions, and other factors.

Sentiment

Score: 4

Explanation: The document discloses a non-binding acquisition proposal. While an offer itself can be seen as positive for liquidity, the proposed price of $7.22 per share is drastically lower than Biogen's initial investment price of $104.14 per share, indicating a significant negative revaluation for Sage's stock from the perspective of prior investors and potentially for Sage's standalone value.

Positives

• For Biogen, the proposal offers an opportunity to gain full control over the jointly developed assets, zuranolone and SAGE-324, and potentially integrate Sage's pipeline and operations.
• The proposed acquisition price of $7.22 per share represents a cash offer for Sage Therapeutics shareholders, providing liquidity.
• The existing collaboration framework provides a foundation for a potential full integration, potentially streamlining development and commercialization efforts for key neurological and psychiatric therapies.

Negatives

• The proposed acquisition price of $7.22 per share is significantly lower than the approximately $104.14 per share Biogen MA paid for its initial 10.2% stake in December 2020, indicating a substantial loss for Biogen on its initial investment and a low valuation for Sage's remaining shareholders.
• The proposal is non-binding, meaning there is no assurance that a transaction will be consummated, or that its terms or timing will remain as proposed.
• The potential delisting of Sage's Common Stock from the Nasdaq Global Market could reduce liquidity for remaining shareholders if the transaction proceeds.

Risks

• The proposal is non-binding and may be modified or withdrawn at any time, with no assurance of consummation.
• The transaction, if undertaken, could result in the delisting of Sage's Common Stock from the Nasdaq Global Market.
• Potential for significant changes to Sage's business or corporate structure, including changes in management or the board of directors, if the acquisition proceeds.
• Biogen may acquire additional securities or dispose of its current holdings, which could impact Sage's share price and market dynamics.
• The market price for Sage's securities, general market, industry, and economic conditions, and changes in law and government regulations could influence Biogen's future actions regarding its investment.

Future Outlook

Biogen intends to regularly review its investment in Sage Therapeutics and reserves the right to acquire additional securities, dispose of current holdings, or pursue extraordinary corporate transactions, including mergers, delisting, or changes to Sage's business or corporate structure. The proposal is non-binding and may be modified or withdrawn.

Management Comments

• Biogen delivered a non-binding proposal to the chief executive officer of Sage Therapeutics to acquire all outstanding shares of Common Stock not owned by Biogen or its subsidiaries for $7.22 per share in cash.

Industry Context

This announcement highlights a potential consolidation within the biopharmaceutical sector, specifically in neurology and psychiatric disorders. Biogen, a major player in these therapeutic areas, is seeking to potentially fully integrate assets from its existing collaboration with Sage Therapeutics, a company focused on brain health. This move could reflect Biogen's strategy to deepen its pipeline in these specialized areas or to gain full control over promising drug candidates like zuranolone and SAGE-324, which are critical for major depressive disorder, postpartum depression, and essential tremor.

Related Party Transactions

• The existing Collaboration and License Agreement (November 27, 2020) and Stock Purchase Agreement (November 27, 2020) between Sage Therapeutics and Biogen MA (a Biogen subsidiary) are related party transactions.
• The current non-binding acquisition proposal from Biogen to acquire the remaining shares of Sage Therapeutics is a related party transaction, building on their existing collaborative and ownership relationship.

Stakeholder Impact

• Shareholders of Sage Therapeutics: Face a potential cash-out at $7.22 per share, which is significantly lower than the price Biogen initially paid for its stake, potentially resulting in substantial losses for many investors.
• Employees of Sage Therapeutics: May experience uncertainty or changes in employment, corporate culture, or strategic direction if the acquisition proceeds.
• Customers/Patients: Potential for changes in the development and commercialization strategy for zuranolone and SAGE-324, which could impact access or future therapeutic options.
• Biogen (as a shareholder and acquirer): Stands to gain full control over key collaborative assets and Sage's pipeline, potentially enhancing its position in neurology and psychiatric markets, but also acknowledging a significant write-down on its initial investment.

Next Steps

• Biogen will regularly review its investment in Sage Therapeutics.
• Biogen may acquire additional securities of Sage (including Common Stock) through open market purchases, privately negotiated transactions, or otherwise.
• Biogen may dispose of all or a portion of its securities of Sage in the open market, in publicly or privately negotiated transactions, or in underwritten offerings.
• Biogen may engage in discussions with Sage's management, board of directors, stockholders, and other relevant parties.
• Biogen may encourage or seek to cause Sage or such persons to consider or explore extraordinary corporate transactions involving Sage, including mergers, acquisitions/dispositions of assets or businesses, repurchases or changes to capitalization, or other material changes to business or corporate structure, including changes in management or board composition.

Key Dates

Keywords

Biogen, Sage Therapeutics, Acquisition Proposal, Schedule 13D, Biopharmaceutical, Merger, Zuranolone, SAGE-217, SAGE-324, Major Depressive Disorder, Postpartum Depression, Essential Tremor, Neurology, Psychiatric Disorders, Stock Purchase Agreement, Collaboration Agreement